Colin Simpson

Jun 13, 2024 | nature.com | Calum Macdonald |Norah E Palmateer |Laura Lindsay |Safraj Shahul Hameed |Karen Jeffrey |Luke Daines | +9 more

AbstractSeveral population-level studies have described individual clinical risk factors associated with suboptimal antibody responses following COVID-19 vaccination, but none have examined multimorbidity. Others have shown that suboptimal post-vaccination responses offer reduced protection to subsequent SARS-CoV-2 infection; however, the level of protection from COVID-19 hospitalisation/death remains unconfirmed.

Jun 13, 2024 | nature.com | Calum Macdonald |Norah E Palmateer |Laura Lindsay |Safraj Shahul Hameed |Karen Jeffrey |Luke Daines | +9 more

AbstractSeveral population-level studies have described individual clinical risk factors associated with suboptimal antibody responses following COVID-19 vaccination, but none have examined multimorbidity. Others have shown that suboptimal post-vaccination responses offer reduced protection to subsequent SARS-CoV-2 infection; however, the level of protection from COVID-19 hospitalisation/death remains unconfirmed.

Oct 12, 2023 | thelancet.com | Colin Simpson |Chris Robertson |Jim McMenamin

The Scottish Early Estimation of Pandemic Influenza Antiviral and Vaccine Effectiveness (EAVE) platform was established in 2012 through funding from the National Institute for Health Research, alongside a portfolio of nine pandemic preparedness and responsiveness projects consequent to the 2009 influenza A/H1N1 pandemic.In response to the emergence of COVID-19, funding was made available by a range of UK funders to support studies that could rapidly respond to this new pandemic.